Globus Medical, Inc. (GMED) News
Follow Globus Medical, Inc. (GMED) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Globus Medical Reports Q3 Results, Cuts 2026 Revenue Guidance
Globus Medical reported Q3 net sales of $763.7 million, down 0.7% year over year, and GAAP diluted EPS of $1.04, up 18.2%. It increased its share repurchase program by $500 million and lowered 2026 revenue guidance to $3
EQUITY | Nov 05, 2026, 11:03 PM UTC
L
Globus Medical 3Q 2026: Revenue $763.72M, EPS $1.04 — 10-Q Summary
Globus Medical’s third-quarter net sales declined 0.7% year over year, while earnings increased as lower selling, general and administrative expenses—primarily reduced litigation provisions—and lower product costs more t
EARNINGS | Nov 05, 2026, 10:12 PM UTC
M
Globus Medical Reports Q3 Results, Adds $500 Million to Buyback Program
Globus Medical reported third-quarter revenue of $764 million, down slightly, and announced a $500 million increase to its share repurchase program.
EQUITY | Nov 05, 2026, 09:09 PM UTC
L
Globus Medical 3Q Sales $763.7M >GMED
Globus Medical 3Q Sales $763.7M >GMED
EQUITY | Nov 05, 2026, 09:05 PM UTC
L
Globus Medical 3Q Net $141.2M >GMED
Globus Medical 3Q Net $141.2M >GMED
EQUITY | Nov 05, 2026, 09:02 PM UTC
L
Globus Medical 3Q EPS $1.04 >GMED
Globus Medical 3Q EPS $1.04 >GMED
EARNINGS | Nov 05, 2026, 09:02 PM UTC
M
Globus Medical Acquires Synaptive Medical
EQUITY | Nov 03, 2026, 09:05 PM UTC
H
Globus Medical Q2 2026 Earnings Call Transcript
On Thursday, Globus Medical (NYSE: GMED ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and tra
LIVE | Oct 12, 2026, 09:56 AM UTC
L
Prim Extends Distribution Contract With Globus Medical Until 2033
Prim SA BME:PRM
NEWS | Sep 23, 2026, 02:56 PM UTC
H
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it w
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance fol
EARNINGS | Sep 08, 2026, 04:05 PM UTC
L
Globus Medical gets CE Mark for Excelsius3D imaging system
Globus Medical announced CE Mark approval for its Excelsius3D™ imaging system.
EQUITY | Sep 03, 2026, 08:37 PM UTC
M
Globus Medical to acquire Higgs Boson Health
Globus Medical (GMED) announced an acquisition of Higgs Boson Health to transform the healthcare experience via AI-driven digital solutions.
MNA | Aug 26, 2026, 09:57 PM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
L
Globus Medical Raises FY2026 Adj EPS Guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B
Globus Medical (NYSE: GMED ) raises FY2026 Adj EPS guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180 billion-$3.220 billion vs $
EARNINGS | Aug 06, 2026, 08:32 PM UTC
L
ATEC Initiate with a Buy, GMED initiate with a Neutral @ UBS
ATEC Initiate with a Buy, GMED initiate with a Neutral @ UBS
EQUITY | Jul 28, 2026, 11:50 AM UTC
L
GMED Initiated Neutral W/$82.00 PT at UBS
GMED Initiated Neutral W/$82.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
EQUITY | Jul 21, 2026, 12:24 PM UTC
H
BMO Capital starts Globus Medical at Outperform on earnings power
As previously reported, BMO Capital initiated coverage of Globus Medical with an Outperform rating and $94 price target. The market continues to underappreciate the earnings power of the fully integrated platform, the an
EQUITY | Jul 08, 2026, 08:30 PM UTC
H
Globus Medical price target lowered to $80 from $95 at Stifel
Stifel analyst Thomas Stephan lowered the firm's price target on Globus Medical to $80 from $95 and keeps a Hold rating on the shares. 2026 revenue expectations are being lowered toward the low end of guidance due to wea
EARNINGS | Jul 08, 2026, 11:03 AM UTC